GYRE Gyre Therapeutics, Inc.
7.040USD-0.56%Mkt Cap: 746.48M $P/E: —1d ago
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfe…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates Cytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||